<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136380</url>
  </required_header>
  <id_info>
    <org_study_id>206817</org_study_id>
    <nct_id>NCT03136380</nct_id>
  </id_info>
  <brief_title>Study of Danirixin in Japanese Healthy Elderly Male Subjects</brief_title>
  <official_title>A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an Open Label, 2-way Crossover to Evaluate Food Effect on the Pharmacokinetics of Danirixin (Part2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Danirixin is a selective chemokine receptor antagonist being developed as a potential
      anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD).
      The aim of the study is to assess the safety, tolerability and pharmacokinetics (PK) in
      healthy Japanese subjects over the age of 65 years (inclusive). The study will be conducted
      in two parts: Part 1 will be a double blind, placebo-controlled, 3-period crossover,
      ascending single oral dose administration of GSK1325756H (Hydrobromide Salt Tablet
      Formulations of Danirixin) 10, 50 and 100 milligram (mg) in the fed condition. Part 2 will be
      an open label, 2-period crossover, single oral dose of GSK1325756H 50 mg in fed and fasted
      state. This study will provide an understanding of PK of hydrobromide salt of GSK1325756 in
      population of healthy elderly subjects and also contribute to the selection of appropriate
      dosing for Phase IIa study in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1</measure>
    <time_frame>Up to 32 days in Part 1</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Safety population comprised of all participants who took at least one dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</measure>
    <time_frame>Up to 21 days in Part 2</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, High Density Lipids (HDL) Cholesterol, Potassium, Low Density Lipids (LDL) Cholesterol,Sodium,Phosphorus,Triglycerides,Urea/Blood Urea Nitrogen (BUN) in Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, and urea/BUN results for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, HDL Cholesterol, Potassium, LDL Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, urea/BUN results for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, ALT, AST, Creatine Kinase, GGT and Lactate Dehydrogenase for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of chemistry parameter namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Hemoglobin for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Hematocrit for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Hemoglobin for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Hematocrit for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 1</measure>
    <time_frame>Up to 72 hours in Part 1</time_frame>
    <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 72 hours in Part 1. Only categories with significant values have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part 1</measure>
    <time_frame>Up to 72 hours in Part 1</time_frame>
    <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Specific Gravity Analysis by Dipstick Method for Part 1</measure>
    <time_frame>Up to 72 hours in Part 1</time_frame>
    <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 2</measure>
    <time_frame>Up to 48 hours in Part 2</time_frame>
    <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 48 hours in Part 2. Only categories with significant values have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine pH Analysis by Dipstick Method for Part 2</measure>
    <time_frame>Up to 48 hours in Part 2</time_frame>
    <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by dipstick method up to 48 hours in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Specific Gravity Analysis by Dipstick Method for Part 2</measure>
    <time_frame>Up to 72 hours in Part 2</time_frame>
    <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 48 hours in Part 2. Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 1. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameter Heart Rate for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 1. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameter Temperature for Part 1</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 1. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameters SBP and DBP for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 2. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameter Heart Rate for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 2. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Parameter Temperature for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 2. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT Frederica's Correction) Interval</measure>
    <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
    <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 1 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Fridericia's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Electrocardiogram Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT (Frederica's Correction) Interval for Part 2</measure>
    <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
    <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 2 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Frederica's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Concentration of GSK1325756 in Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of part 1. Data has been presented for blood concentrations of GSK1325756 in fed state. Pharmacokinetic (PK) population was defined as participants who were administered at least one dose of study treatment and who had PK sample taken and analyzed. NA indicates standard deviation could not be calculated due to high proportion of non-quantifiable [NQ] values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation and no sample was obtained per protocol for 60 and 72 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Concentration of GSK1325756 in Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in part 1. Data has been presented for blood concentrations of GSK1325756 in fasted and fed state. NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag Time Before Observable Concentration (Tlag) of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of GSK1325756H for Part 1</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-24) of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tlag of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tlast of the Blood Concentration of GSK1325756H for Part 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 post-dose in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Part 1: Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1325756H</intervention_name>
    <description>Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.</description>
    <arm_group_label>Part 1: Group A</arm_group_label>
    <arm_group_label>Part 1: Group B</arm_group_label>
    <arm_group_label>Part 1: Group C</arm_group_label>
    <arm_group_label>Part 2: Group D</arm_group_label>
    <arm_group_label>Part 2: Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.</description>
    <arm_group_label>Part 1: Group A</arm_group_label>
    <arm_group_label>Part 1: Group B</arm_group_label>
    <arm_group_label>Part 1: Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Participant must be over 65 years of age inclusive, at the time of signing the
             informed consent.

          -  Participants who are overtly healthy as determined by medical evaluation including
             medical history, physical examination, laboratory tests, and ECG. A subject with a
             clinical abnormality or laboratory parameter(s) which is/are not specifically listed
             in the inclusion or exclusion criteria, outside the reference range for the population
             being studied may be included only if the investigator in consultation with the
             Medical Monitor if required agree that the finding is unlikely to introduce additional
             risk factors and will not interfere with the study procedures.

          -  Participants whose peripheral blood neutrophil counts and hematocrit values are within
             normal range at screening visit.

          -  Body weight &gt;=50 kilogram (Kg) and body mass index (BMI) within the range 18.5-24.9
             kg/square meter (m^2) (inclusive).

          -  Japanese Male: A male participant must agree to use contraception during the treatment
             period and until follow up visit.

          -  Capable of giving signed informed consent.

        Exclusion Criteria

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrine, hematological, or neurological disorders capable of significantly altering
             the absorption, metabolism, or elimination of drugs; constituting a risk when taking
             the study treatment; or interfering with the interpretation of data.

          -  Abnormal blood pressure as determined by the investigator.

          -  Alanine Aminotransferase (ALT)&gt;1.5x upper limit of normal (ULN).

          -  Bilirubin&gt;1.5xULN (isolated bilirubin &gt; 1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt; 35%).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  QT interval corrected for heart rate according to Fridericia's formula (QTcF)&gt; 450
             millisecond (msec).

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications and proton pump inhibitor (PPI) within 14 days prior to dosing.

          -  History of donation of blood or blood products &gt;=400 milliliter (mL) within 3 months
             or &gt;=200 mL within 1 month prior to screening.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Current enrolment or past participation within the last 30 days before signing of
             consent in this clinical study involving an investigational study treatment or any
             other type of medical research.

          -  The subject with positive Serological test for syphilis (Rapid Plasma Reagin [RPR] and
             Treponema pallidum hemagglutination test [TPHA]), Human immunodeficiency virus (HIV)
             Antigen/Antibody, Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV)
             antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody at screening.

          -  Positive pre-study drug screen.

          -  Regular alcohol consumption within 6 months prior to the study defined as: an average
             weekly intake of &gt; 14 units for males. One unit is equivalent to 350 mL of beer, 150
             mL of wine or 45 mL of 80 proof distilled spirits.

          -  Smoking or history or regular use of tobacco- or nicotine-containing products within 6
             months prior to screening.

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or medical monitor, contraindicates
             participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Japanese Healthy Elderly Male Subjects</gender_description>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>162-00</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <results_first_submitted>June 1, 2018</results_first_submitted>
  <results_first_submitted_qc>January 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2019</results_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy Japanese subjects</keyword>
  <keyword>CXCR2 inhibitor</keyword>
  <keyword>Danirixin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03136380/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03136380/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single center in Tokyo, Japan from 10-May-2017 to 31-July-2017.</recruitment_details>
      <pre_assignment_details>A total of 147 participants were screened of which 113 were screen failures the reasons of which were investigator discretion (1), lost to follow-up (2) screened but enrollment target reached prior to enrollment (5) and did not met inclusion/exclusion criteria (105). A total of 18 participants in Part 1 and 16 in Part 2 were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1-GSK1325756H 10 mg Then GSK1325756H 50 mg Then Placebo</title>
          <description>Participants in this arm received GSK1325756H 10 milligrams (mg) in treatment period 1 followed by GSK1325756H 50 mg in treatment period 2 followed by placebo in treatment period 3. The treatment periods were separated were separated by a minimum of one-week washout period.</description>
        </group>
        <group group_id="P2">
          <title>Part 1-GSK1325756H 10 mg Then Placebo Then GSK1325756H 100 mg</title>
          <description>Participants in this arm received GSK1325756H 10 mg in treatment period 1 followed placebo in treatment period 2 followed by GSK1325756H 100 mg in treatment period 3. The treatment periods were separated were separated by a minimum of one-week washout period.</description>
        </group>
        <group group_id="P3">
          <title>Part 1-Placebo Then GSK1325756H 50 mg Then GSK1325756H 100 mg</title>
          <description>Participants in this arm received placebo in treatment period 1 followed by GSK1325756H 50 mg in treatment period 2 followed by GSK1325756H 100 mg in treatment period 3. The treatment periods were separated were separated by a minimum of one-week washout period.</description>
        </group>
        <group group_id="P4">
          <title>Part 2-GSK1325756H Fed Followed by Fasted</title>
          <description>Participants were randomized to receive GSK1325756H 50 mg (fed) in Period 1 followed by GSK1325756H (fasted) in Period 2 of Part 2. The treatment periods were separated were separated by a minimum of one-week washout period.</description>
        </group>
        <group group_id="P5">
          <title>Part 2-GSK1325756H Fasted Followed by Fed</title>
          <description>Participants were randomized to receive GSK1325756H 50 mg (fasted) in Period 1 followed by GSK1325756H (fed) in Period 2 of Part 2. The treatment periods were separated were separated by a minimum of one-week washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1, Period 1 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1, Period 3 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 1 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1-Total Participants</title>
          <description>Participants received a single dose of GSK1325756H 10 mg (fed), GSK1325756 50 mg (fed), GSK1325756 100 mg (fed) and matching placebo in one of the three treatment periods in a crossover manner. The treatment periods were separated by a minimum of one-week washout period. The maximum duration of participation of participants, in Part 1 was 24 days.</description>
        </group>
        <group group_id="B2">
          <title>Part 2-Total Participants</title>
          <description>Participants received a single dose of GSK1325756 50 mg (fed) and GSK1325756 50 mg (fasted) in one of the two treatment periods in a crossover manner. The treatment periods were separated by a minimum of one-week washout period. The maximum duration of participation of participants, in Part 2 was 13 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="3.01"/>
                    <measurement group_id="B2" value="69.3" spread="2.89"/>
                    <measurement group_id="B3" value="69.6" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese/East Asian /South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Safety population comprised of all participants who took at least one dose of study treatment.</description>
        <time_frame>Up to 32 days in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Safety population comprised of all participants who took at least one dose of study treatment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant</description>
        <time_frame>Up to 21 days in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, High Density Lipids (HDL) Cholesterol, Potassium, Low Density Lipids (LDL) Cholesterol,Sodium,Phosphorus,Triglycerides,Urea/Blood Urea Nitrogen (BUN) in Part 1</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, and urea/BUN results for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, High Density Lipids (HDL) Cholesterol, Potassium, Low Density Lipids (LDL) Cholesterol,Sodium,Phosphorus,Triglycerides,Urea/Blood Urea Nitrogen (BUN) in Part 1</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, and urea/BUN results for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Millimoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0208" spread="0.04617"/>
                    <measurement group_id="O2" value="-0.0187" spread="0.04137"/>
                    <measurement group_id="O3" value="0.0021" spread="0.05675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0000" spread="0.06312"/>
                    <measurement group_id="O4" value="-0.0318" spread="0.05124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0453" spread="0.36206"/>
                    <measurement group_id="O2" value="0.0129" spread="0.30588"/>
                    <measurement group_id="O3" value="0.1681" spread="0.53220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2241" spread="0.62379"/>
                    <measurement group_id="O4" value="-0.0541" spread="0.37997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.11"/>
                    <measurement group_id="O2" value="1.9" spread="1.83"/>
                    <measurement group_id="O3" value="1.9" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.17"/>
                    <measurement group_id="O4" value="1.5" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2452" spread="0.27852"/>
                    <measurement group_id="O2" value="0.3516" spread="0.34246"/>
                    <measurement group_id="O3" value="0.1619" spread="0.32580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2776" spread="0.16088"/>
                    <measurement group_id="O4" value="0.1463" spread="0.38958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1789" spread="0.16035"/>
                    <measurement group_id="O2" value="-0.1702" spread="0.12302"/>
                    <measurement group_id="O3" value="-0.1228" spread="0.13910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1509" spread="0.11380"/>
                    <measurement group_id="O4" value="-0.2304" spread="0.10753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.162"/>
                    <measurement group_id="O2" value="0.11" spread="0.231"/>
                    <measurement group_id="O3" value="0.28" spread="0.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.294"/>
                    <measurement group_id="O4" value="0.07" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0065" spread="0.35150"/>
                    <measurement group_id="O2" value="0.0043" spread="0.26961"/>
                    <measurement group_id="O3" value="0.0711" spread="0.44012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1896" spread="0.56007"/>
                    <measurement group_id="O4" value="-0.0188" spread="0.36555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.00"/>
                    <measurement group_id="O2" value="1.4" spread="2.07"/>
                    <measurement group_id="O3" value="0.9" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.89"/>
                    <measurement group_id="O4" value="1.1" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1588" spread="0.12039"/>
                    <measurement group_id="O2" value="-0.1399" spread="0.08525"/>
                    <measurement group_id="O3" value="-0.1426" spread="0.09972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0969" spread="0.05776"/>
                    <measurement group_id="O4" value="-0.1262" spread="0.11041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6422" spread="0.31917"/>
                    <measurement group_id="O2" value="0.4963" spread="0.36405"/>
                    <measurement group_id="O3" value="0.5575" spread="0.38005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3823" spread="0.34016"/>
                    <measurement group_id="O4" value="0.4910" spread="0.21744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7140" spread="0.79099"/>
                    <measurement group_id="O2" value="-0.5355" spread="1.14422"/>
                    <measurement group_id="O3" value="-0.1785" spread="0.95672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2975" spread="0.41735"/>
                    <measurement group_id="O4" value="-0.5193" spread="0.96276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase for Part 1</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase for Part 1</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>International units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="9.08"/>
                    <measurement group_id="O2" value="-1.5" spread="8.44"/>
                    <measurement group_id="O3" value="0.0" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase,72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="13.37"/>
                    <measurement group_id="O4" value="4.6" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.89"/>
                    <measurement group_id="O2" value="-0.5" spread="3.92"/>
                    <measurement group_id="O3" value="-1.9" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.83"/>
                    <measurement group_id="O4" value="0.6" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="4.38"/>
                    <measurement group_id="O2" value="-0.6" spread="4.52"/>
                    <measurement group_id="O3" value="-2.2" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.67"/>
                    <measurement group_id="O4" value="-1.4" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="27.10"/>
                    <measurement group_id="O2" value="-34.3" spread="23.83"/>
                    <measurement group_id="O3" value="-32.3" spread="22.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.7" spread="9.99"/>
                    <measurement group_id="O4" value="-46.4" spread="32.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.48"/>
                    <measurement group_id="O2" value="0.9" spread="1.44"/>
                    <measurement group_id="O3" value="-1.9" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.10"/>
                    <measurement group_id="O4" value="-0.1" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="20.20"/>
                    <measurement group_id="O2" value="-13.8" spread="11.66"/>
                    <measurement group_id="O3" value="-12.0" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="49.15"/>
                    <measurement group_id="O4" value="-17.3" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 1</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 1</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Grams/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.44"/>
                    <measurement group_id="O2" value="-0.6" spread="1.44"/>
                    <measurement group_id="O3" value="0.3" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.32"/>
                    <measurement group_id="O4" value="-1.0" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.59"/>
                    <measurement group_id="O2" value="-0.3" spread="1.82"/>
                    <measurement group_id="O3" value="0.8" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.64"/>
                    <measurement group_id="O4" value="0.0" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 1</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 1</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.428" spread="0.7734"/>
                    <measurement group_id="O2" value="0.000" spread="1.2629"/>
                    <measurement group_id="O3" value="-0.712" spread="0.8805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.855" spread="1.4307"/>
                    <measurement group_id="O4" value="-0.466" spread="0.7987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.283" spread="2.0784"/>
                    <measurement group_id="O2" value="-0.428" spread="3.3513"/>
                    <measurement group_id="O3" value="-1.425" spread="1.9060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.565" spread="4.6830"/>
                    <measurement group_id="O4" value="-2.332" spread="1.7560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9890" spread="4.33275"/>
                    <measurement group_id="O2" value="-3.6833" spread="3.21689"/>
                    <measurement group_id="O3" value="-1.8417" spread="3.02629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7147" spread="3.73658"/>
                    <measurement group_id="O4" value="-4.0985" spread="3.79755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.7053" spread="25.78160"/>
                    <measurement group_id="O2" value="-33.7053" spread="17.26380"/>
                    <measurement group_id="O3" value="-31.7227" spread="21.57043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7573" spread="43.97767"/>
                    <measurement group_id="O4" value="-23.2513" spread="23.10621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 1</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 1</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="9.16"/>
                    <measurement group_id="O2" value="20.6" spread="18.05"/>
                    <measurement group_id="O3" value="22.7" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="28.84"/>
                    <measurement group_id="O4" value="14.4" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, HDL Cholesterol, Potassium, LDL Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN for Part 2</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, urea/BUN results for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Laboratory Parameters Calcium, Cholesterol, Chloride, Glucose, HDL Cholesterol, Potassium, LDL Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN for Part 2</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely calcium, cholesterol, chloride, glucose, HDL cholesterol, potassium, LDL cholesterol, sodium, phosphorus, triglycerides, urea/BUN results for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" spread="0.05834"/>
                    <measurement group_id="O2" value="0.0000" spread="0.05154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3119" spread="0.37218"/>
                    <measurement group_id="O2" value="0.3588" spread="0.25265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.01"/>
                    <measurement group_id="O2" value="0.5" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2116" spread="0.23744"/>
                    <measurement group_id="O2" value="0.1561" spread="0.35643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1131" spread="0.12629"/>
                    <measurement group_id="O2" value="-0.0808" spread="0.10678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.377"/>
                    <measurement group_id="O2" value="0.14" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1729" spread="0.30124"/>
                    <measurement group_id="O2" value="0.2279" spread="0.27614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.65"/>
                    <measurement group_id="O2" value="0.8" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus inorganic, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0868" spread="0.08561"/>
                    <measurement group_id="O2" value="-0.1433" spread="0.08821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7402" spread="0.43390"/>
                    <measurement group_id="O2" value="0.6010" spread="0.39556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6024" spread="1.44409"/>
                    <measurement group_id="O2" value="-0.3347" spread="0.90755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, ALT, AST, Creatine Kinase, GGT and Lactate Dehydrogenase for Part 2</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Alkaline Phosphatase, ALT, AST, Creatine Kinase, GGT and Lactate Dehydrogenase for Part 2</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely alkaline phosphatase, ALT, AST, creatine kinase, GGT and lactate dehydrogenase for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>International units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="9.96"/>
                    <measurement group_id="O2" value="6.5" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.93"/>
                    <measurement group_id="O2" value="-1.5" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.28"/>
                    <measurement group_id="O2" value="-1.8" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="28.72"/>
                    <measurement group_id="O2" value="-16.6" spread="18.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.99"/>
                    <measurement group_id="O2" value="-0.4" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="11.97"/>
                    <measurement group_id="O2" value="-13.7" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 2</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein for Part 2</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely albumin and total protein for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Grams/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.54"/>
                    <measurement group_id="O2" value="0.8" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.66"/>
                    <measurement group_id="O2" value="1.9" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 2</title>
        <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid for Part 2</title>
          <description>Blood samples were collected for the assessment of chemistry parameters namely direct bilirubin, total bilirubin, creatinine and uric acid for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.641" spread="1.5135"/>
                    <measurement group_id="O2" value="-0.641" spread="1.2291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.496" spread="4.6254"/>
                    <measurement group_id="O2" value="-0.748" spread="2.6468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8178" spread="3.68348"/>
                    <measurement group_id="O2" value="-4.2542" spread="3.32677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6135" spread="54.03085"/>
                    <measurement group_id="O2" value="-8.5502" spread="75.89141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 2</title>
        <description>Blood samples were collected for the assessment of chemistry parameter namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameter Amylase for Part 2</title>
          <description>Blood samples were collected for the assessment of chemistry parameter namely amylase for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="8.63"/>
                    <measurement group_id="O2" value="18.5" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.221"/>
                    <measurement group_id="O2" value="0.09" spread="0.168"/>
                    <measurement group_id="O3" value="0.09" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.082"/>
                    <measurement group_id="O4" value="0.03" spread="0.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="1.132"/>
                    <measurement group_id="O2" value="0.95" spread="1.301"/>
                    <measurement group_id="O3" value="0.73" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.753"/>
                    <measurement group_id="O4" value="0.54" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="4.754"/>
                    <measurement group_id="O2" value="5.35" spread="5.907"/>
                    <measurement group_id="O3" value="4.39" spread="4.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="3.363"/>
                    <measurement group_id="O4" value="2.85" spread="7.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.677"/>
                    <measurement group_id="O2" value="0.01" spread="1.093"/>
                    <measurement group_id="O3" value="-0.12" spread="0.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.652"/>
                    <measurement group_id="O4" value="0.16" spread="1.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.56" spread="5.347"/>
                    <measurement group_id="O2" value="-6.40" spread="7.071"/>
                    <measurement group_id="O3" value="-5.10" spread="4.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="3.946"/>
                    <measurement group_id="O4" value="-3.57" spread="9.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Hemoglobin for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Hemoglobin for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Grams/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.66"/>
                    <measurement group_id="O2" value="4.8" spread="4.24"/>
                    <measurement group_id="O3" value="5.5" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="5.23"/>
                    <measurement group_id="O4" value="5.0" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Hematocrit for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Hematocrit for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0188" spread="0.01542"/>
                    <measurement group_id="O2" value="0.0177" spread="0.01293"/>
                    <measurement group_id="O3" value="0.0238" spread="0.01599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0255" spread="0.01472"/>
                    <measurement group_id="O4" value="0.0121" spread="0.01700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean corpuscle hemoglobin, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.376"/>
                    <measurement group_id="O2" value="-0.10" spread="0.429"/>
                    <measurement group_id="O3" value="-0.14" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle hemoglobin, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.479"/>
                    <measurement group_id="O4" value="0.25" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean corpuscle volume, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.78"/>
                    <measurement group_id="O2" value="0.3" spread="0.65"/>
                    <measurement group_id="O3" value="1.3" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.75"/>
                    <measurement group_id="O4" value="0.2" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Giga cells/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelet count, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="14.59"/>
                    <measurement group_id="O2" value="1.4" spread="12.55"/>
                    <measurement group_id="O3" value="0.5" spread="15.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="11.33"/>
                    <measurement group_id="O4" value="2.3" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count,48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.489"/>
                    <measurement group_id="O2" value="-0.48" spread="0.956"/>
                    <measurement group_id="O3" value="-0.67" spread="0.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count,72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.471"/>
                    <measurement group_id="O4" value="-0.75" spread="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 1</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 1</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 1. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Trillion cells/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cell count, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165" spread="0.1650"/>
                    <measurement group_id="O2" value="0.164" spread="0.1385"/>
                    <measurement group_id="O3" value="0.197" spread="0.1797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.252" spread="0.1609"/>
                    <measurement group_id="O4" value="0.120" spread="0.1680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocyte count, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0127" spread="0.01512"/>
                    <measurement group_id="O2" value="0.0038" spread="0.01765"/>
                    <measurement group_id="O3" value="-0.0009" spread="0.01929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocyte count, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0023" spread="0.01646"/>
                    <measurement group_id="O4" value="-0.0037" spread="0.01780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely basophils, eosinophils, leukocytes, lymphocytes, monocytes, total neutrophils and platelets for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.250"/>
                    <measurement group_id="O2" value="0.09" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.082"/>
                    <measurement group_id="O2" value="0.67" spread="0.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="7.821"/>
                    <measurement group_id="O2" value="4.53" spread="5.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.873"/>
                    <measurement group_id="O2" value="-0.63" spread="0.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" spread="9.311"/>
                    <measurement group_id="O2" value="-4.66" spread="6.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Hemoglobin for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Hemoglobin for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Grams/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="3.92"/>
                    <measurement group_id="O2" value="8.9" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Hematocrit for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Hematocrit for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely hematocrit for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0304" spread="0.01286"/>
                    <measurement group_id="O2" value="0.0268" spread="0.01303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.312"/>
                    <measurement group_id="O2" value="0.20" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter Mean Corpuscle Volume for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameter namely mean corpuscle volume for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.96"/>
                    <measurement group_id="O2" value="0.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Platelet Count and White Blood Cell Count for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely platelet count and white blood cell count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Giga cells/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelet count, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="15.32"/>
                    <measurement group_id="O2" value="13.1" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count,48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.45" spread="0.995"/>
                    <measurement group_id="O2" value="-0.36" spread="0.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 2</title>
        <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters Red Blood Count and Reticulocyte Count for Part 2</title>
          <description>Blood samples were collected for the assessment of hematology parameters namely red blood count and reticulocyte count for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Trillion cells/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cell count, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.318" spread="0.1462"/>
                    <measurement group_id="O2" value="0.255" spread="0.1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocyte count, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0018" spread="0.01203"/>
                    <measurement group_id="O2" value="0.0097" spread="0.01526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 1</title>
        <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 72 hours in Part 1. Only categories with significant values have been presented.</description>
        <time_frame>Up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 1</title>
          <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 72 hours in Part 1. Only categories with significant values have been presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine occult blood, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine occult blood, + , 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine occult blood, Trace, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine occult blood, + , 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein, Trace, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine urobilinogen, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine urobilinogen, Trace, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part 1</title>
        <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part 1</title>
          <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine pH, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" spread="0.634"/>
                    <measurement group_id="O2" value="6.17" spread="0.389"/>
                    <measurement group_id="O3" value="6.42" spread="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="0.492"/>
                    <measurement group_id="O4" value="6.36" spread="0.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Specific Gravity Analysis by Dipstick Method for Part 1</title>
        <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
        <time_frame>Up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Specific Gravity Analysis by Dipstick Method for Part 1</title>
          <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 72 hours in Part 1. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0167" spread="0.00753"/>
                    <measurement group_id="O2" value="NA" spread="NA">NA indicates no sample was obtained per protocol for GSK1325756H 10 mg (fed) and GSK1325756H 50 mg (fed) at 72 hours post dose</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA indicates no sample was obtained per protocol for GSK1325756H 10 mg (fed) and GSK1325756H 50 mg (fed) at 72 hours post dose</measurement>
                    <measurement group_id="O4" value="1.0150" spread="0.00224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 2</title>
        <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 48 hours in Part 2. Only categories with significant values have been presented.</description>
        <time_frame>Up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Values on Urinalysis by Dipstick Method for Part 2</title>
          <description>Urinalysis parameters assessed were urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen. In this dipstick test, the level of bilirubin, occult blood, glucose, ketones, urine protein and urobilinogen in urine samples was recorded as negative, trace and +. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 48 hours in Part 2. Only categories with significant values have been presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine occult blood, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine glucose, Trace , 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine urobilinogen, Trace, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine urobilinogen, +, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine pH Analysis by Dipstick Method for Part 2</title>
        <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by dipstick method up to 48 hours in Part 2.</description>
        <time_frame>Up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine pH Analysis by Dipstick Method for Part 2</title>
          <description>Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by dipstick method up to 48 hours in Part 2.</description>
          <population>Safety Population</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="0.724"/>
                    <measurement group_id="O2" value="6.47" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Specific Gravity Analysis by Dipstick Method for Part 2</title>
        <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 48 hours in Part 2. Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
        <time_frame>Up to 72 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Specific Gravity Analysis by Dipstick Method for Part 2</title>
          <description>Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Urine samples were collected for the measurement of urine specific gravity by dipstick method up to 48 hours in Part 2. Density is the mass per unit volume and has units (such as g/cm^3), however, the specific gravity is a ratio so it has no unit.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0153" spread="0.00618"/>
                    <measurement group_id="O2" value="1.0159" spread="0.00712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) for Part 1</title>
        <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 1. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) for Part 1</title>
          <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 1. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="10.44"/>
                    <measurement group_id="O2" value="-9.6" spread="9.21"/>
                    <measurement group_id="O3" value="-4.2" spread="6.59"/>
                    <measurement group_id="O4" value="-0.3" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="7.95"/>
                    <measurement group_id="O2" value="0.5" spread="13.61"/>
                    <measurement group_id="O3" value="1.7" spread="6.87"/>
                    <measurement group_id="O4" value="4.5" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="7.06"/>
                    <measurement group_id="O2" value="7.0" spread="10.76"/>
                    <measurement group_id="O3" value="5.9" spread="11.66"/>
                    <measurement group_id="O4" value="2.0" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="8.06"/>
                    <measurement group_id="O4" value="4.8" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="5.89"/>
                    <measurement group_id="O2" value="-2.8" spread="3.33"/>
                    <measurement group_id="O3" value="-2.2" spread="4.93"/>
                    <measurement group_id="O4" value="-1.1" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="4.94"/>
                    <measurement group_id="O2" value="4.5" spread="4.58"/>
                    <measurement group_id="O3" value="0.8" spread="6.40"/>
                    <measurement group_id="O4" value="1.0" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.24"/>
                    <measurement group_id="O2" value="4.7" spread="6.07"/>
                    <measurement group_id="O3" value="2.1" spread="4.44"/>
                    <measurement group_id="O4" value="2.5" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.12"/>
                    <measurement group_id="O4" value="1.8" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameter Heart Rate for Part 1</title>
        <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 1. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameter Heart Rate for Part 1</title>
          <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 1. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.92"/>
                    <measurement group_id="O2" value="-3.2" spread="8.24"/>
                    <measurement group_id="O3" value="-3.7" spread="6.17"/>
                    <measurement group_id="O4" value="-2.9" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.67"/>
                    <measurement group_id="O2" value="-7.5" spread="9.23"/>
                    <measurement group_id="O3" value="-3.8" spread="4.97"/>
                    <measurement group_id="O4" value="-2.2" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.09"/>
                    <measurement group_id="O2" value="1.2" spread="7.51"/>
                    <measurement group_id="O3" value="-2.3" spread="6.59"/>
                    <measurement group_id="O4" value="-2.7" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.98"/>
                    <measurement group_id="O4" value="-1.0" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameter Temperature for Part 1</title>
        <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 1. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameter Temperature for Part 1</title>
          <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 1. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.363"/>
                    <measurement group_id="O2" value="0.07" spread="0.400"/>
                    <measurement group_id="O3" value="0.27" spread="0.393"/>
                    <measurement group_id="O4" value="0.14" spread="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.269"/>
                    <measurement group_id="O2" value="0.01" spread="0.375"/>
                    <measurement group_id="O3" value="0.06" spread="0.394"/>
                    <measurement group_id="O4" value="0.05" spread="0.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.362"/>
                    <measurement group_id="O2" value="-0.02" spread="0.364"/>
                    <measurement group_id="O3" value="0.01" spread="0.387"/>
                    <measurement group_id="O4" value="0.12" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.179"/>
                    <measurement group_id="O4" value="0.17" spread="0.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameters SBP and DBP for Part 2</title>
        <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 2. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameters SBP and DBP for Part 2</title>
          <description>Vital sign measurements included SBP and DBP at Baseline and up to 72 hours in Part 2. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="11.70"/>
                    <measurement group_id="O2" value="-2.5" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="12.13"/>
                    <measurement group_id="O2" value="-3.5" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="10.22"/>
                    <measurement group_id="O2" value="-0.2" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="6.19"/>
                    <measurement group_id="O2" value="-0.3" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="6.66"/>
                    <measurement group_id="O2" value="-0.6" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.80"/>
                    <measurement group_id="O2" value="0.8" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameter Heart Rate for Part 2</title>
        <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 2. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameter Heart Rate for Part 2</title>
          <description>Vital sign measurements included heart rate at Baseline and up to 72 hours in Part 2. Heart rate measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.69"/>
                    <measurement group_id="O2" value="-1.8" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.46"/>
                    <measurement group_id="O2" value="-0.1" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.83"/>
                    <measurement group_id="O2" value="0.5" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vital Sign Parameter Temperature for Part 2</title>
        <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 2. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Sign Parameter Temperature for Part 2</title>
          <description>Vital sign measurements included temperature at Baseline and up to 72 hours in Part 2. Temperature measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions and were measured in a supine position after 5 minutes rest. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.236"/>
                    <measurement group_id="O2" value="0.21" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.250"/>
                    <measurement group_id="O2" value="0.10" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.228"/>
                    <measurement group_id="O2" value="0.10" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT Frederica's Correction) Interval</title>
        <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 1 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Fridericia's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
        <time_frame>Baseline and up to 72 hours in Part 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo (Fed)</title>
            <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT Frederica's Correction) Interval</title>
          <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 1 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Fridericia's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).</description>
          <population>Safety Population</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="11.65"/>
                    <measurement group_id="O2" value="0.7" spread="5.28"/>
                    <measurement group_id="O3" value="1.3" spread="4.29"/>
                    <measurement group_id="O4" value="0.5" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="5.63"/>
                    <measurement group_id="O2" value="3.0" spread="7.56"/>
                    <measurement group_id="O3" value="4.3" spread="6.20"/>
                    <measurement group_id="O4" value="3.6" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="9.22"/>
                    <measurement group_id="O2" value="-0.8" spread="8.50"/>
                    <measurement group_id="O3" value="5.7" spread="9.18"/>
                    <measurement group_id="O4" value="5.8" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="11.57"/>
                    <measurement group_id="O4" value="6.0" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.12"/>
                    <measurement group_id="O2" value="-0.3" spread="2.39"/>
                    <measurement group_id="O3" value="-0.2" spread="1.59"/>
                    <measurement group_id="O4" value="-0.2" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.89"/>
                    <measurement group_id="O2" value="0.7" spread="1.97"/>
                    <measurement group_id="O3" value="0.7" spread="1.56"/>
                    <measurement group_id="O4" value="0.4" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.97"/>
                    <measurement group_id="O2" value="2.8" spread="1.99"/>
                    <measurement group_id="O3" value="1.7" spread="1.87"/>
                    <measurement group_id="O4" value="0.5" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.34"/>
                    <measurement group_id="O4" value="0.9" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="10.98"/>
                    <measurement group_id="O2" value="-4.2" spread="15.90"/>
                    <measurement group_id="O3" value="-4.0" spread="10.23"/>
                    <measurement group_id="O4" value="-2.9" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="10.74"/>
                    <measurement group_id="O2" value="6.8" spread="15.69"/>
                    <measurement group_id="O3" value="-1.0" spread="9.82"/>
                    <measurement group_id="O4" value="-1.5" spread="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="8.69"/>
                    <measurement group_id="O2" value="-6.8" spread="12.52"/>
                    <measurement group_id="O3" value="-1.5" spread="11.48"/>
                    <measurement group_id="O4" value="-0.2" spread="14.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="13.29"/>
                    <measurement group_id="O4" value="-4.5" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="5.32"/>
                    <measurement group_id="O2" value="-11.3" spread="5.14"/>
                    <measurement group_id="O3" value="-10.8" spread="7.16"/>
                    <measurement group_id="O4" value="-8.1" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="6.39"/>
                    <measurement group_id="O2" value="-8.3" spread="7.75"/>
                    <measurement group_id="O3" value="-9.5" spread="4.83"/>
                    <measurement group_id="O4" value="-6.5" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.45"/>
                    <measurement group_id="O2" value="-5.9" spread="7.44"/>
                    <measurement group_id="O3" value="-10.7" spread="6.51"/>
                    <measurement group_id="O4" value="-6.9" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval,, 72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="3.27"/>
                    <measurement group_id="O4" value="-7.6" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Electrocardiogram Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT (Frederica's Correction) Interval for Part 2</title>
        <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 2 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Frederica's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
        <time_frame>Baseline and up to 48 hours in Part 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram Parameters PR Interval, QRS Duration, Uncorrected QT Interval and Corrected QT (Frederica's Correction) Interval for Part 2</title>
          <description>Single 12-lead ECG's were obtained from Baseline and up to 72 hours in Part 2 using an ECG machine that automatically calculated the heart rate and measured PR Interval, QRS Duration, Uncorrected QT interval and Corrected QT (Frederica's correction) interval. Baseline was defined as pre-dose assessments performed on Day 1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value.</description>
          <population>Safety Population</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="5.59"/>
                    <measurement group_id="O2" value="-0.6" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="7.50"/>
                    <measurement group_id="O2" value="1.3" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="8.84"/>
                    <measurement group_id="O2" value="4.1" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.28"/>
                    <measurement group_id="O2" value="-1.3" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.19"/>
                    <measurement group_id="O2" value="-1.8" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.50"/>
                    <measurement group_id="O2" value="-0.9" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="12.31"/>
                    <measurement group_id="O2" value="6.4" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="15.85"/>
                    <measurement group_id="O2" value="-3.9" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="11.25"/>
                    <measurement group_id="O2" value="-9.5" spread="17.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="6.55"/>
                    <measurement group_id="O2" value="3.1" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="6.73"/>
                    <measurement group_id="O2" value="-3.8" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QT Interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.58"/>
                    <measurement group_id="O2" value="-7.3" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Concentration of GSK1325756 in Part 1</title>
        <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of part 1. Data has been presented for blood concentrations of GSK1325756 in fed state. Pharmacokinetic (PK) population was defined as participants who were administered at least one dose of study treatment and who had PK sample taken and analyzed. NA indicates standard deviation could not be calculated due to high proportion of non-quantifiable [NQ] values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation and no sample was obtained per protocol for 60 and 72 hours.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Concentration of GSK1325756 in Part 1</title>
          <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of part 1. Data has been presented for blood concentrations of GSK1325756 in fed state. Pharmacokinetic (PK) population was defined as participants who were administered at least one dose of study treatment and who had PK sample taken and analyzed. NA indicates standard deviation could not be calculated due to high proportion of non-quantifiable [NQ] values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation and no sample was obtained per protocol for 60 and 72 hours.</description>
          <population>PK Population</population>
          <units>Nanograms/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood concentration, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O3" value="0.000" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.425" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="9.289" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O3" value="32.318" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.350" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="151.658" spread="196.5556"/>
                    <measurement group_id="O3" value="201.782" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.75 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.951" spread="67.9706"/>
                    <measurement group_id="O2" value="373.193" spread="376.8749"/>
                    <measurement group_id="O3" value="426.032" spread="611.1420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.150" spread="86.0423"/>
                    <measurement group_id="O2" value="455.042" spread="350.7416"/>
                    <measurement group_id="O3" value="634.955" spread="767.2316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration,, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.395" spread="100.0463"/>
                    <measurement group_id="O2" value="971.417" spread="598.1981"/>
                    <measurement group_id="O3" value="1285.524" spread="1017.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.733" spread="67.6734"/>
                    <measurement group_id="O2" value="950.852" spread="443.1637"/>
                    <measurement group_id="O3" value="1235.273" spread="740.0601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.417" spread="47.6187"/>
                    <measurement group_id="O2" value="966.658" spread="395.2375"/>
                    <measurement group_id="O3" value="1498.000" spread="607.8816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.817" spread="37.7057"/>
                    <measurement group_id="O2" value="639.667" spread="251.0068"/>
                    <measurement group_id="O3" value="1418.545" spread="497.2105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.567" spread="25.8472"/>
                    <measurement group_id="O2" value="386.667" spread="153.4840"/>
                    <measurement group_id="O3" value="735.700" spread="234.1135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.358" spread="16.1098"/>
                    <measurement group_id="O2" value="295.250" spread="96.3848"/>
                    <measurement group_id="O3" value="620.636" spread="217.5446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration,12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.742" spread="10.1591"/>
                    <measurement group_id="O2" value="204.192" spread="70.3804"/>
                    <measurement group_id="O3" value="411.091" spread="143.5280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.363" spread="4.9104"/>
                    <measurement group_id="O2" value="77.342" spread="37.3054"/>
                    <measurement group_id="O3" value="160.982" spread="61.3081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.423" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="24.387" spread="13.2219"/>
                    <measurement group_id="O3" value="43.282" spread="17.8091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 60 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA indicates no sample obtained per protocol.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA indicates no sample obtained per protocol.</measurement>
                    <measurement group_id="O3" value="19.087" spread="11.6452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA indicates no sample obtained per protocol.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA indicates no sample obtained per protocol.</measurement>
                    <measurement group_id="O3" value="18.403" spread="12.5176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Concentration of GSK1325756 in Part 2</title>
        <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in part 1. Data has been presented for blood concentrations of GSK1325756 in fasted and fed state. NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Concentration of GSK1325756 in Part 2</title>
          <description>Whole blood samples of approximately 1 milliliters were collected for measurement of blood concentrations of GSK1325756 at Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in part 1. Data has been presented for blood concentrations of GSK1325756 in fasted and fed state. NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</description>
          <population>PK Population</population>
          <units>Nanograms/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood concentration, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="0.000" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.888" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="434.557" spread="551.7663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.749" spread="NA">NA indicates standard deviation could not be calculated due to high proportion of NQ values (more than 30% of values were imputed i.e., NQ assigned zero concentration) which affected the standard deviation.</measurement>
                    <measurement group_id="O2" value="2233.813" spread="1476.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 0.75 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.644" spread="745.3481"/>
                    <measurement group_id="O2" value="3599.500" spread="1240.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.700" spread="711.2266"/>
                    <measurement group_id="O2" value="4210.625" spread="1361.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1039.688" spread="638.7844"/>
                    <measurement group_id="O2" value="3176.000" spread="691.7762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1499.250" spread="657.7378"/>
                    <measurement group_id="O2" value="2156.250" spread="521.9307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1682.667" spread="478.1134"/>
                    <measurement group_id="O2" value="1960.625" spread="402.0194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774.938" spread="305.5721"/>
                    <measurement group_id="O2" value="640.500" spread="140.6840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.750" spread="143.7101"/>
                    <measurement group_id="O2" value="410.625" spread="105.4564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364.438" spread="117.3348"/>
                    <measurement group_id="O2" value="350.813" spread="112.8440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration,12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.938" spread="76.6059"/>
                    <measurement group_id="O2" value="254.188" spread="68.8847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.163" spread="43.6251"/>
                    <measurement group_id="O2" value="118.888" spread="53.3676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood concentration, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.568" spread="61.6334"/>
                    <measurement group_id="O2" value="29.918" spread="32.5396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1:GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.082" spread="17.8"/>
                    <measurement group_id="O2" value="1219.883" spread="37.3"/>
                    <measurement group_id="O3" value="1924.864" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1622.2891" spread="21.7"/>
                    <measurement group_id="O2" value="8872.6074" spread="30.2"/>
                    <measurement group_id="O3" value="16681.8331" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1779.0163" spread="18.8"/>
                    <measurement group_id="O2" value="9253.2108" spread="31.3"/>
                    <measurement group_id="O3" value="17072.6642" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1500.0109" spread="14.7"/>
                    <measurement group_id="O2" value="7831.8861" spread="29.9"/>
                    <measurement group_id="O3" value="14000.5473" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50000" lower_limit="2.0000" upper_limit="6.0000"/>
                    <measurement group_id="O2" value="3.00000" lower_limit="2.0000" upper_limit="6.0000"/>
                    <measurement group_id="O3" value="4.00000" lower_limit="2.0000" upper_limit="6.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53043" spread="2.938579"/>
                    <measurement group_id="O2" value="11.17318" spread="2.284423"/>
                    <measurement group_id="O3" value="13.15755" spread="4.540486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lag Time Before Observable Concentration (Tlag) of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time Before Observable Concentration (Tlag) of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756 in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37500" lower_limit="0.0000" upper_limit="1.0000"/>
                    <measurement group_id="O2" value="0.25000" lower_limit="0.0000" upper_limit="2.0000"/>
                    <measurement group_id="O3" value="0.25000" lower_limit="0.0000" upper_limit="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of GSK1325756H for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in all 3 periods; 60 and 72 hours post-dose in period-3 of Part 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK1325756H 10 mg (Fed)</title>
            <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK1325756H 100 mg (Fed)</title>
            <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of GSK1325756H for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00000" lower_limit="24.0000" upper_limit="48.0000"/>
                    <measurement group_id="O2" value="48.00000" lower_limit="48.0000" upper_limit="48.0000"/>
                    <measurement group_id="O3" value="72.00000" lower_limit="48.0000" upper_limit="72.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1818.544" spread="32.5"/>
                    <measurement group_id="O2" value="4146.886" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11880.9038" spread="28.9"/>
                    <measurement group_id="O2" value="18303.0441" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-inf) of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf) of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12143.8862" spread="28.8"/>
                    <measurement group_id="O2" value="18910.7975" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-24) of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-24) of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10433.9293" spread="25.8"/>
                    <measurement group_id="O2" value="16856.0664" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00000" lower_limit="0.5000" upper_limit="6.0000"/>
                    <measurement group_id="O2" value="1.00000" lower_limit="0.5000" upper_limit="3.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times. Only those participants with data available at the indicated time points were analyzed.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75500" spread="2.928804"/>
                    <measurement group_id="O2" value="11.09246" spread="5.259109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tlag of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlag of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25000" lower_limit="0.0000" upper_limit="1.0000"/>
                    <measurement group_id="O2" value="0.00000" lower_limit="0.00000" upper_limit="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tlast of the Blood Concentration of GSK1325756H for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 post-dose in Part 2</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK1325756H 50 mg (Fed)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
            <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 milliliters of water in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast of the Blood Concentration of GSK1325756H for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of GSK1325756H in fasted state. PK parameters were calculated by standard non-compartmental analysis using Phoenix WinNonlin Version 6.4 or higher based on actual sampling times.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00000" lower_limit="24.0000" upper_limit="48.0000"/>
                    <measurement group_id="O2" value="48.00000" lower_limit="48.0000" upper_limit="48.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from the Day -1 up to follow-up ( 32 days for Part 1 and up to 21 days for Part 2)</time_frame>
      <desc>Safety Population was used for analysis of AE and SAE's.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Placebo (Fed)</title>
          <description>Participants received matching placebo tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: GSK1325756H 10 mg (Fed)</title>
          <description>Participants received GSK1325756H 10 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: GSK1325756H 50 mg (Fed)</title>
          <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: GSK1325756H 100 mg (Fed)</title>
          <description>Participants received GSK1325756H 100 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 2: GSK1325756H 50 mg (Fed)</title>
          <description>Participants received GSK1325756H 50 mg tablets via the oral route with food (fed state) and 240 milliliters of water in Part 2.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: GSK1325756H 50 mg (Fasted)</title>
          <description>Participants received GSK1325756H 50 mg tablets via the oral route without food (fasted state) and 240 mililiters of water in Part 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

